J
Jake Powrie
Researcher at St Thomas' Hospital
Publications - 37
Citations - 1905
Jake Powrie is an academic researcher from St Thomas' Hospital. The author has contributed to research in topics: Diabetes mellitus & Type 1 diabetes. The author has an hindex of 21, co-authored 36 publications receiving 1699 citations. Previous affiliations of Jake Powrie include Medical Research Council & National Health Service.
Papers
More filters
Journal ArticleDOI
Monitoring blood glucose control in diabetes mellitus: a systematic review.
TL;DR: The citations in retrieved papers were examined and non-English language papers were included as too few articles were retrieved by searches restricted to English language publications only.
Journal ArticleDOI
Self-monitoring in Type 2 Diabetes Mellitus: A Meta-Analysis
TL;DR: In this article, the authors evaluated the effectiveness of self-monitoring of blood or urine glucose at improving blood glucose control through a systematic review and meta-analysis, and concluded that the results do not provide evidence for clinical effectiveness of an item of care with appreciable costs.
Journal ArticleDOI
Peripheral and Islet Interleukin-17 Pathway Activation Characterizes Human Autoimmune Diabetes and Promotes Cytokine-Mediated β-Cell Death
Sefina Arif,Fabrice Moore,Katherine Marks,Thomas Bouckenooghe,Colin M. Dayan,Raquel Planas,Marta Vives-Pi,Jake Powrie,Timothy Tree,Piero Marchetti,Guo Cai Huang,Esteban Nicolas Gurzov,Ricardo Pujol-Borrell,Decio L. Eizirik,Mark Peakman +14 more
TL;DR: It is shown that IL-17 mediates significant and reproducible enhancement of IL-1β/interferon (IFN)-γ–induced and tumor necrosis factor (TNF)-α/IFN-γ-induced apoptosis in human islets, rat β-cells, and INS-1E cells, in association with significant upregulation of β-cell IL17RA expression via activation of the transcription factors STAT1 and nuclear factor (NF)-κB.
Journal ArticleDOI
Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes
Sefina Arif,Pia Leete,Vy Nguyen,Katherine Marks,Nurhanani Mohamed Nor,Megan Estorninho,Deborah Kronenberg-Versteeg,Polly J. Bingley,John A. Todd,Catherine Guy,David B. Dunger,Jake Powrie,Abby Willcox,Alan K. Foulis,Sarah J. Richardson,Emanuele de Rinaldis,Noel G. Morgan,Anna Lorenc,Mark Peakman +18 more
TL;DR: It is concluded that different immunopathological processes (endotypes) may underlie type 1 diabetes, carrying important implications for treatment and prevention strategies.
Journal ArticleDOI
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes
Mohammad Alhadj Ali,Yuk-Fun Liu,Yuk-Fun Liu,Sefina Arif,Danijela Tatovic,Hina Shariff,Vivienne B. Gibson,Norkhairin Yusuf,Roman Baptista,Martin Eichmann,Nedyalko Petrov,Susanne Heck,Jennie H M Yang,Timothy Tree,Irma Pujol-Autonell,Lorraine Yeo,Lucas Baumard,Rachel Stenson,Alex Howell,Alison Clark,Zoe Boult,Jake Powrie,Laura Adams,Florence Susan Wong,Stephen D. Luzio,Gareth Dunseath,Kate Green,Alison O'Keefe,Graham Bayly,Natasha Thorogood,Robert Andrews,Nicola Leech,Frank Joseph,Sunil Nair,Susan Seal,HoYee Cheung,Craig A. Beam,Robert Kerrin Hills,Mark Peakman,Mark Peakman,Colin M. Dayan +40 more
TL;DR: Proinsulin peptide immunotherapy is safe, does not accelerate decline in β cell function, and is associated with antigen-specific and nonspecific immune modulation.